



















Obesity is defined clinically as a state of increased body
weight, more specifically of increased fat tissue mass. It is
associated with increased fat cell size and number, and is
usually followed by serious health consequences if not
controlled. Body weight and the storage of energy as
triglyceride in adipose tissue are determined by the
interaction between genetic, metabolic, environmental,
and psychological factors. These influences ultimately act
by changing the balance between energy intake and
expenditure.1
Obesity is a prevalent health hazard, both in developed
and developing countries, and is associated with a
number of pathological disorders, including hypertension,
type 2 diabetes mellitus, cardiovascular disease (CVD),
cancer, gallstones, respiratory system problems, and sleep
apnoea. The degree of health impairment is determined
by three factors: first is the amount of fat, second is the
distribution of fat and third is the presence of other risk
factors. The fat deposition may be generalised, or may
occur preferentially in different adipose tissue
compartments. Two major variants of obesity are
distinguished for their differential impact on morbidity,
viz. truncal and peripheral obesity.2
Predominant accumulation of fat in the truncal area,
which includes subcutaneous and visceral fat divisions, is
the main feature of android obesity. This form of obesity is
more often found in men and is associated with high risk
of CVD, independent of generalised adiposity.
Accumulation of fat in the gluteofemoral area is the main
feature of gynoid obesity, which is more frequently found
in premenopausal women and apparently is not
associated with increased risk of CVD.2
Hypertension 
According to the World Health Organization (WHO), up to
20% of the population in developed countries may suffer
from obesity-associated hypertension.3 Obesity alone
possibly accounts for 78% and 65% of essential
hypertension in men and women respectively.4 The
prevalence of high blood pressure in obese adults is 38.4%
for men and 32.2% for women, compared with 18.2% for
men and 16.5% for women with a body mass index (BMI)
less than 25 kg/m2.5
Some of the major characteristics associated with obesity-
associated hypertension in humans are activation of the
renin-angiotensin system,6-8 high levels of circulating
leptin5, 9 and activation of the sympathetic nervous
system.6, 9 Leptin may be an important factor in the
aetiology of obesity-associated hypertension as it
increases sympathetic activity and may mediate
increases in catecholamines and activation of the renin-
angiotensin system. Angiotensin II levels are high in
obesity, which may result from the secretion of
angiotensinogen from adipocytes10 and the presence of
increased glomerular pressures suggest activation of the
renin-angiotensin system.11
Studies have shown that losing weight leads to decreased
blood pressure. Weight loss is associated with reductions
in vascular resistance, total blood volume and cardiac
output, improvement in insulin resistance, reduction in
sympathetic nervous system activity, and suppression of
the activity of the renin-angiotensin-aldosterone system.9
Diabetes mellitus
The association between obesity and type 2 diabetes
mellitus is well recognised.12 A majority of patients with
type 2 diabetes are obese, approximately 85 - 95% in most
population studies.13 However only 10% of obese patients
are diabetic,14 suggesting that obesity alone is not
sufficient to cause type 2 diabetes. Other factors are also
required, most especially islet beta-cell dysfunction.15
The risk of developing diabetes increases by
approximately 25% for each additional unit of BMI over
22 kg/m2.16 It has been found that weight gain is
responsible for 27% of new cases of type 2 diabetes in the
USA17 and that the prevalence of type 2 diabetes
correlates strongly (r = 0.64) with the prevalence of
obesity.18 Both cross-sectional19-21 and longitudinal
studies22 have indicated that central obesity is a strong
risk factor for type 2 diabetes.21, 22
Obesity increases insulin resistance and glucose
intolerance and via these metabolic effects plays a major
role in the pathophysiology of type 2 diabetes. Insulin
resistance may present 10 - 20 years before onset of the
disease, and is considered to be the best predictor of
whether or not an individual will later become diabetic.23
The mechanism by which obesity leads to insulin
resistance is uncertain. However, much experimental
evidence exists to demonstrate that adipocytes secrete a
number of factors that may play a role in the control of
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insulin sensitivity. These include adiponectin, interleukin-
6 (IL-6), tumour necrosis factor α (TNF-α), resistin, free
fatty acids and cortisol.24 It has also been demonstrated
that obesity leads to increased deposition of triglycerides
within skeletal muscle and that the level of intramuscular
triglyceride correlates negatively with insulin sensitivity.25
Obesity not only increases the risk of developing type 2
diabetes but also complicates its management. The
presence of obesity exacerbates metabolic abnormalities
of type 2 diabetes, including hyperglycaemia,
hyperinsulinaemia and dyslipidaemia. Obesity may
contribute to excessive morbidity in type 2 diabetics as
the risk of developing hypertension and cardiovascular
disease increase with the coexistence of obesity and
diabetes.13
Coronary heart disease (CHD)
The negative effects of obesity on health and
cardiovascular disease are well documented.26-29 Body
weight independent of traditional risk factors is directly
related to the development of CHD. A study by Willett
et al.30 showed that overweight and obese women have an
increased risk of CHD of 2- and 3.6-fold respectively. An
increase in weight of up to 11 kg increases the risk of
disease 1.6-fold, while an increase in weight of 11 - 19 kg
increases the risk 1.9-fold. The risk of CHD increases 3-
fold when the BMI passes 29 kg/m2 compared with the
risk in lean subjects.30
The nature of the postulated association between insulin
resistance and CHD remains obscure. It has been
suggested that tissue insulin resistance is the primary
initiating defect that leads to compensatory
hyperinsulinaemia and an increase in atherogenic risk
factors.31 Also, visceral adipose tissue, which has been
shown to be associated with increased insulin resistance,
is the strongest predictor of cardiovascular disease in
white and African-American women.29
Increased body mass also has mechanical effects on the
cardiovascular system. Total body oxygen consumption is
increased as a result of expanded tissue mass and the
oxidative demands of metabolically active adipose tissue,
and this is associated with an absolute increase in cardiac
output. Total blood volume is increased in proportion to
body weight, and this will contribute to an increase in the
left ventricular preload and an increase in resting cardiac
output.32 Increased cardiac output is achieved by an
increase in stroke volume while the heart rate remains
comparatively unchanged. The obesity-related increase in
stroke volume results from an increase in diastolic filling
of the left ventricle.26 The volume expansion and increase
in cardiac output leads to structural changes of the heart,
and the increase in left ventricular filling results in an
increase in the left ventricular cavity dimension and an
increase in wall stress.26
Observational studies33 have shown that obesity and
excess abdominal fat are directly related to cardiovascular
risk factors, including high levels of total cholesterol, low-
density lipoprotein (LDL) cholesterol, triglycerides, blood
pressure, fibrinogen and insulin and low levels of high-
density lipoprotein (HDL) cholesterol. It has also been
suggested that both obesity and CHD are
proinflammatory states and that adipose tissue secretes a
number of proinflammatory cytokines that may be
involved in the aetiology of CHD.34
Cancer
Breast cancer accounts for approximately 20% of all
female cancers, with 80% of cases occurring in
postmenopausal women.35 More than 100 epidemiological
studies have examined the relationship between breast
cancer and BMI, fat distribution, and weight gain at
different ages.36 These studies have shown that women
who were overweight or obese had a 30 - 50% greater risk
of postmenopausal breast cancer development than leaner
women. In contrast, overweight and obesity are
associated with a lower risk of breast cancer developing
during the premenopausal years. The International
Agency for Research on Cancer (IARC) estimates that 25%
of breast cancer cases worldwide are the result of obesity
and a sedentary lifestyle.37
The Women’s Health Initiative (WHI) Observational
Study38 is a multi-ethnic, multisite cohort study of women
aged 50 - 79 years at study entry. Women underwent
several measures of adiposity on entering the study.
Analysis of these data showed that anthropometric factors
were associated with breast cancer risk, but only among
those women who had never used hormone replacement
therapy (HRT).38 The risk of developing breast cancer in
obese women with BMIs above 31.1 kg/m2 was 2.5 times
higher than in women with BMIs less than 22.6 kg/m2.
Similarly, the Nurses Health Study39 found a 60% greater
risk of postmenopausal breast cancer associated with
overweight and obesity in women who had never used
HRT. 
Data from cohort studies38-40 demonstrate that abdominal
obesity is associated with an approximate doubling of
breast cancer risk among postmenopausal women,
independent of BMI. In the WHI study,38 a statistically
significant trend of increasing breast cancer risk with
increasing waist circumference, but not waist-hip ratio,
was observed. This finding was limited to women who
had never used HRT.38
Obese men and women have a much higher risk of
developing colon cancer. Studies have shown that when
the BMI is greater than 24 kg/m2 the chances of
developing colon cancer double and triple when the BMI
passes 30 kg/m2.41 Colon cancer in men is positively
associated with obesity, while in women this relationship
is weaker.42 Studies have shown that increased
consumption of dietary fat, especially animal fat, is
associated with the development of colon43, 44 and
colorectal cancer.45
A number of other cancer types have been found to be
more prevalent in obese subjects. Obese women have a
risk of endometrial cancer three times greater than
women with normal weight.46 Studies have also shown a
positive association between prostate cancer and BMI,47, 48
and body weight.49 A Swedish study50 detected a
relationship between obesity and a number of different
cancer types. The researchers detected a 33% excess
incidence of cancer among the obese subjects (25% more
among men and 37% more among women). The obese
patients had an increased risk of Hodgkin’s disease and
cancers of the endometrium, kidney, gallbladder, colon,
pancreas, bladder, cervix, ovary and brain.
The mechanism by which obesity may give rise to an
increased risk of cancer is not known. However, it has
been suggested that in the case of breast cancer the
higher level of bioavailable oestrogen in obese subjects
may play some role.51
Gallstones 
Gallstones are concretions in the gallbladder or bile duct
and are composed chiefly of a mixture of cholesterol,
calcium bilirubinate and calcium carbonate; occasionally
there are pure stones composed of just one of these
substances. The prevalence of gallstones has been found
to be high in obese subjects. The probability of gallstone
formation increased 2.7-fold in women with BMIs above
40 kg/m2 compared with women with BMIs less than 24.9
kg/m2, while in men the probability increased 2.3-fold for
the same categories.52 The process by which obesity may
lead to gallstone formation is not fully understood;
however, it is known that precipitation of cholesterol
within the bile is involved. This precipitation may be
induced by a number of factors, including a cholesterol
solubility defect, the presence of nucleating factors and
increased residence time of bile within the gallbladder
because of reduced mobility.53 Gallstone formation is also
associated with weight loss. The risk of gallstone
formation increased from 44% when obese women lost 4 -
10 kg, to 94% when they lost more than 10 kg.28 However,
it has been suggested that it is the underlying obesity
rather than the weight loss that is the predominant cause
of gallstone formation.
Osteoarthritis 
Osteoarthritis is characterised by erosion of articular
cartilage, either primary or secondary to trauma or other
conditions. The cartilage becomes soft, frayed, and
thinned with eburnation of the subchondral bone and
outgrowths of marginal osteophytes, pain and loss of































more common in older people. Overweight or obese
people are at high risk of developing osteoarthritis.54-57 In a
study54 of twin, middle-aged women, it was estimated
that for every kilogram increase in weight the risk of
developing osteoarthritis increased by 9 - 13%, while
another study58 demonstrated that at least two-thirds of
osteoarthritis patients were overweight at the time of
their surgery.
Sleep apnoea and other respiratory
system problems 
Obesity has a negative effect on lung function. However,
this effect differs according to the degree of obesity, the
kind of obesity (abdominal or peripheral) and age. Studies
on animals have shown that obesity affects the
respiratory system by reducing total lung volume and
functional residual capacity. Abdominal obesity causes
pressure on the diaphragm, decreasing the ability of the
lung to expand during inspiration, while accumulation of
fat on the chest reduces the chest cavity space.59, 60
Sleep apnoea is characterised by recurrent episodes of
cessation of respiratory airflow caused by occlusion in the
upper airway  during sleep, with a consequent decrease
in oxygen saturation. Obesity is considered to be a very
important factor affecting sleep apnoea. Many cross-
sectional studies have confirmed the relationship between
increased body weight and the risk of sleep apnoea.61
Significant sleep apnoea is present in about 40% of obese
individuals62 and 70% of sleep apnoea patients are obese.
In one study63 a 10% increase in body weight was
associated with a 6-fold increase in the risk of developing
sleep apnoea. Health consequences such as arterial
hypoxia, increased sympathetic tone, and pulmonary and
systemic hypertension are usually associated with severe
cases.64
The exact mechanisms underlying the relationship
between obesity and sleep apnoea are still unclear. It may
be related to the effect of fat deposition on airway
anatomy or changes in upper airway function.62 Weight
loss has been shown to be associated with a decrease in
upper airway collapsibility in obstructive sleep apnoea.65
A number of studies have demonstrated a relationship
between BMI and the prevalence and severity of asthma
in children and adults.66 In the American Nurses Health
Study II67 BMI was found to be a positive predictor of
asthma development, while a study from Finland68 has
shown that weight reduction in obese asthmatics leads
to improvements in both lung function and asthma
symptoms. However the role played by obesity in the
aetiology of asthma is not known.
Obesity and reproductive function
Obesity is related to menstrual abnormalities, infertility
and miscarriage. Obesity is associated with menstrual
abnormalities including cycles longer than 36 days,
irregular cycles, and virile hair growth with facial hair.69 It
has also been shown that the risk of subsequent ovulatory
infertility is increased by elevated BMI at the age of 18
years, even in women who are not considered obese.70
Studies have reported that obesity during pregnancy is
accompanied by increased hypertension, gestational
diabetes, congenital malformations, and morbidity of both
mother and child.71, 72 Furthermore, induction of labour,
delivery by emergency caesarean section, and postpartum
haemorrhage are reported to be more common in obese
pregnant women than in their normal counterparts.72, 73
Spontaneous abortion is more common in pregnancies
complicated by obesity, and can occur in pregnancies
resulting from natural conception and from treatment with
assisted reproductive technology (ART).74 Obesity has also
been demonstrated to reduce fertility substantially in the
general population, and to reduce pregnancy rates greatly
when using ART.75, 76
Polycystic ovary syndrome (PCOS) is the association of
hyperandrogenism with chronic anovulation in women
without specific underlying diseases of the adrenal or
pituitary glands. PCOS is associated with obesity,
particularly abdominal obesity.77 Two important factors
contribute to PCOS in obese women – the high
production of oestrogen compared with their lean
counterparts, and the low production of sex hormone-
binding globulin (SHBG), which is accompanied by an
elevated free biologically active fraction of oestradiol.78
Insulin resistance is considered to be pivotal in the
expression of PCOS, and is highly associated with
abdominal obesity. Direct or indirect reduction in insulin
concentrations increase ovarian activity78 and the
treatment of PCOS patients with insulin-sensitising
agents leads to a reduction in androgen levels and
improved ovulatory function.79 Reduction in weight has
been found to improve outcomes significantly for obese
subjects. In one study80 of obese infertile women who lost
an average of 10.2 kg on a 6-month exercise and diet
programme the majority resumed spontaneous ovulation
and achieved pregnancy.
Obesity in South Africa
The prevalence of obesity is increasing worldwide,
particularly in developing countries such as South Africa.
This will inevitably lead to an increased prevalence of the
diseases associated with obesity. Indeed, it has been
shown that between the years 2000 and 2010, based on
current trends, the prevalence of type 2 diabetes within
Africa will increase by 50%.81 This will put an increased
financial burden on already overstretched health services.
This can be illustrated by data from the USA showing that
in 1998 overweight- and obesity-attributable medical
spending accounted for 9.1% (equivalent to $78.5 billion)
of total annual USA medical expenditure.82 The prevalence
of obesity in South Africa, as estimated using data
collected in 1998,83 was 10% for males and 30% for
females, compared with data from the USA for the period
1999 - 2000 where the prevalence was 27.6% for men and
33.2% for women.84 Therefore, the prevalence of obesity in
South Africa is reaching a level similar to that in the USA,
which has one of the highest prevalences of obesity in the
world. Data also demonstrate that the prevalence of
obesity-related disorders is high in South Africa.
Metabolic syndrome, which is the grouping together of
dyslipidaemia, insulin resistance, hypertension and
abdominal obesity within the same individual, was found
to be prevalent in 9.1% of black, 10.2% of white and 18.3%
of Indian subjects resident in Johannesburg, and the
prevalence increased with increasing BMI (N H Naran,
N Chetty – unpublished data, 2005). The Medical
Research Council85 has also published data showing that
cardiovascular disease and diabetes mellitus are the
second and tenth leading causes of death in South Africa,
respectively. Obesity-related diseases are therefore a
prime cause of morbidity and mortality in South Africa
and their contribution to the national burden of disease
cannot be ignored. 
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